A trusted adviser to major companies with a chemical industry background, and a Global Expert with the World Economic Forum, Paul Hodges, chairman of New Normal Consulting, reflects on the issues the post-Brexit chemical industry must tackle.
For the report "Value Creation in Chemicals 2020: Bouncing Back from a Year of Adversity", Boston Consulting Group (BCG) analyzed the development of the global chemicals market in the Covid-19 crisis in 2020 and in the years 2015 to 2019 using key figures. The result shows: The current crisis is forcing companies to increase their resilience. The entire value chain, exposure to the end industry, and technical, commercial and digital capabilities must be put to the test in order to respond more effectively to changes in the markets in the future.
A coalescing of factors has led to arrested growth across the chemicals sector this year, with the brand value of the top 25 most valuable chemicals brands contracting by 8% on average, according to the latest report by Brand Finance, an independent brand valuation consultancy.
Alexis Pey, Global SHE & Process Safety Manager at Dutch holding Stahl, talks about the company’s safety culture involving the whole organization.
Within the last 24 months, a whole range of companies announced a series of massive investments in their sites in Flanders, the Northern region of Belgium.
We are in an increasingly volatile global climate, from health and economic crises, to trade wars on multiple fronts, to political unease, to name just a few.
The goal of a CO2-neutral chemical industry in 2050 is comparable with a 30 year marathon – but at sprint speed. So we have to find the best route to this common goal. This is the conclusion of a conference organized by the Association for Chemistry and Economics (VCW), a sub-sector of the German Chemical Society (GDCh).
US chemistry remains in demand around the world despite ongoing trade tensions and Covid-19. In 2019, the US chemical industry was one of the world’s largest exporters, at $136 billion. The industry has a large and growing trade surplus, reaching more than $35 billion in 2019.
While the focus of digitization in Europe and North America is on process efficiency and costs, the focus in Asia-Pacific is on market and customer access.
On Dec. 31, 2020, the UK will leave the EU single market and customs union. Regardless of any agreement reached with the EU, the end of the Brexit transition period will affect citizens, businesses, as well as travel between the UK and EU. Therefore, businesses need to prepare themselves for the upcoming changes.
Investment in the areas listed in the catalogue is supported by a variety of incentives.
The coronavirus crisis caused by the Covid-19 pandemic has uncovered problems that have been smoldering beneath the surface of the pharmaceutical industry — including CMOs/CDMOs and CROs — and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Chemicals are a critical, but often overlooked, factor of success for a circular economy. 96% of all products on European markets, from food to medical treatments, from buildings to consumer electronics, rely on chemicals, so this shouldn’t come as a surprise. But what does circularity mean for the future of the chemicals industry? Should it embrace circular systems or resist them?
Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding, talks about a new innovation management system that will further heighten the importance of innovation in the future.
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.
China`s 14th Five-Year Plan (FYP) covering the period from 2021 to 2025 will only be published after its acceptance by the National People`s Congress in March 2021.
We are in the midst of a start-up revolution. The growth of innovation-driven start-up activity is profound and global in scope, and it is a driving force of change even in mature industries such as the chemical and pharmaceutical sector.
Linde intends to further expand its hydrogen business by investing in electrolysis capacities and infrastructure.
Why BASF Venture Capital is investing in SmartAHC, a supplier of digitalization solutions for pig farming on the Chinese market.
The WeylChem Group of companies consists of seven operating and two R&D sites in Europe and the USA as well as the global sales and marketing platform, WeylChem International.
The chemical industry is on the threshold of a new era – the age of circularity. We asked industry experts to share their opinions on this transformational topic.
Virtual Prototyping of Complex Fluids and Flowing Materials
